FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024615092> ?p ?o ?g. }

• W2024615092 endingPage "657" @default.
• W2024615092 startingPage "650" @default.
• W2024615092 abstract "To evaluate the efficacy of a combination of capecitabine, oxaliplatin, and radiotherapy (RT) in the neoadjuvant treatment of Stage II and III rectal cancers.Capecitabine was given at 725 mg/m(2) orally twice daily Monday through Friday concurrently with RT. Oxaliplatin was given intravenously at 50 mg/m(2) once weekly five times starting the first day of RT. The radiation dose was 50.4 Gy in 28 fractions (1.8 Gy/fraction), five fractions weekly. Endorectal tumor biopsies were obtained before treatment and on the third day of treatment to explore the effects of treatment on thymidine phosphorylase, thymidylate synthase, excision repair cross-complementing rodent repair deficiency complementation group 1 (ERCC1), and apoptosis.A total of 25 patients were enrolled in this study; 6 patients (24%) had a complete pathologic response. T-downstaging occurred in 52% of patients, and N-downstaging occurred in 53%. Grade 3 diarrhea was the most common Grade 3-4 toxicity, occurring in 20% of patients. Only 2 patients experienced disease recurrence, with a median of 20 months of follow-up. Thymidylate synthase, thymidine phosphorylase, ERCC1, and apoptosis did not vary significantly between the pretreatment and Day 3 tumor biopsies, nor did they predict for T-downstaging or a complete pathologic response.Capecitabine at 725 mg/m(2) orally twice daily, oxaliplatin 50 mg/m(2)/wk, and RT at 50.4 Gy is an effective neoadjuvant combination for Stage II and III rectal cancer and results in a greater rate of complete pathologic responses than historically shown in fluoropyrimidine plus RT controls." @default.
• W2024615092 created "2016-06-24" @default.
• W2024615092 creator A5000500580 @default.
• W2024615092 creator A5005718274 @default.
• W2024615092 creator A5006982467 @default.
• W2024615092 creator A5030143515 @default.
• W2024615092 creator A5035002650 @default.
• W2024615092 creator A5036604351 @default.
• W2024615092 creator A5045095134 @default.
• W2024615092 creator A5080659877 @default.
• W2024615092 creator A5087757881 @default.
• W2024615092 creator A5087782164 @default.
• W2024615092 creator A5088972279 @default.
• W2024615092 creator A5091174018 @default.
• W2024615092 date "2008-11-01" @default.
• W2024615092 modified "2023-10-18" @default.
• W2024615092 title "Phase II Study of Weekly Intravenous Oxaliplatin Combined With Oral Daily Capecitabine and Radiotherapy With Biologic Correlates in Neoadjuvant Treatment of Rectal Adenocarcinoma" @default.
• W2024615092 cites W1802949207 @default.
• W2024615092 cites W1963782590 @default.
• W2024615092 cites W1990252673 @default.
• W2024615092 cites W1991199497 @default.
• W2024615092 cites W2019270896 @default.
• W2024615092 cites W2020497218 @default.
• W2024615092 cites W2024035701 @default.
• W2024615092 cites W2025855986 @default.
• W2024615092 cites W2027716910 @default.
• W2024615092 cites W2032375768 @default.
• W2024615092 cites W2057507330 @default.
• W2024615092 cites W2082601343 @default.
• W2024615092 cites W2091400858 @default.
• W2024615092 cites W2095589295 @default.
• W2024615092 cites W2098667099 @default.
• W2024615092 cites W2106633807 @default.
• W2024615092 cites W2108165913 @default.
• W2024615092 cites W2121371996 @default.
• W2024615092 cites W2121489550 @default.
• W2024615092 cites W2125452425 @default.
• W2024615092 cites W2135398482 @default.
• W2024615092 cites W2143655828 @default.
• W2024615092 cites W2143769865 @default.
• W2024615092 cites W2156214772 @default.
• W2024615092 cites W2163776591 @default.
• W2024615092 cites W2171232394 @default.
• W2024615092 cites W2200882253 @default.
• W2024615092 cites W4253234031 @default.
• W2024615092 doi "https://doi.org/10.1016/j.ijrobp.2008.01.020" @default.
• W2024615092 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18565686" @default.
• W2024615092 hasPublicationYear "2008" @default.
• W2024615092 type Work @default.
• W2024615092 sameAs 2024615092 @default.
• W2024615092 citedByCount "31" @default.
• W2024615092 countsByYear W20246150922012 @default.
• W2024615092 countsByYear W20246150922013 @default.
• W2024615092 countsByYear W20246150922014 @default.
• W2024615092 countsByYear W20246150922015 @default.
• W2024615092 countsByYear W20246150922018 @default.
• W2024615092 crossrefType "journal-article" @default.
• W2024615092 hasAuthorship W2024615092A5000500580 @default.
• W2024615092 hasAuthorship W2024615092A5005718274 @default.
• W2024615092 hasAuthorship W2024615092A5006982467 @default.
• W2024615092 hasAuthorship W2024615092A5030143515 @default.
• W2024615092 hasAuthorship W2024615092A5035002650 @default.
• W2024615092 hasAuthorship W2024615092A5036604351 @default.
• W2024615092 hasAuthorship W2024615092A5045095134 @default.
• W2024615092 hasAuthorship W2024615092A5080659877 @default.
• W2024615092 hasAuthorship W2024615092A5087757881 @default.
• W2024615092 hasAuthorship W2024615092A5087782164 @default.
• W2024615092 hasAuthorship W2024615092A5088972279 @default.
• W2024615092 hasAuthorship W2024615092A5091174018 @default.
• W2024615092 hasConcept C121608353 @default.
• W2024615092 hasConcept C123321153 @default.
• W2024615092 hasConcept C126322002 @default.
• W2024615092 hasConcept C126894567 @default.
• W2024615092 hasConcept C143998085 @default.
• W2024615092 hasConcept C2776694085 @default.
• W2024615092 hasConcept C2776735402 @default.
• W2024615092 hasConcept C2777909004 @default.
• W2024615092 hasConcept C2778496288 @default.
• W2024615092 hasConcept C2780456651 @default.
• W2024615092 hasConcept C2780962732 @default.
• W2024615092 hasConcept C509974204 @default.
• W2024615092 hasConcept C526805850 @default.
• W2024615092 hasConcept C71924100 @default.
• W2024615092 hasConcept C90924648 @default.
• W2024615092 hasConceptScore W2024615092C121608353 @default.
• W2024615092 hasConceptScore W2024615092C123321153 @default.
• W2024615092 hasConceptScore W2024615092C126322002 @default.
• W2024615092 hasConceptScore W2024615092C126894567 @default.
• W2024615092 hasConceptScore W2024615092C143998085 @default.
• W2024615092 hasConceptScore W2024615092C2776694085 @default.
• W2024615092 hasConceptScore W2024615092C2776735402 @default.
• W2024615092 hasConceptScore W2024615092C2777909004 @default.
• W2024615092 hasConceptScore W2024615092C2778496288 @default.
• W2024615092 hasConceptScore W2024615092C2780456651 @default.
• W2024615092 hasConceptScore W2024615092C2780962732 @default.
• W2024615092 hasConceptScore W2024615092C509974204 @default.
• W2024615092 hasConceptScore W2024615092C526805850 @default.
• W2024615092 hasConceptScore W2024615092C71924100 @default.

• next